Despite strong revenue growth, the significant share price d...
Despite strong revenue growth, the significant share price drop indicates potential unresolved company challenges. It's advised to scrutinize the stock and forecasts before purchase.
Even After Rising 34% This Past Week, Revance Therapeutics (NASDAQ:RVNC) Shareholders Are Still Down 77% Over the Past Year
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment